查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931237

人类副流感病毒检测套组市场（按产品、技术、最终用户、样本类型和应用划分）－全球预测，2026-2032年

Human Parainfluenza Virus Test Kits Market by Product, Technology, End User, Sample Type, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年人类副流感病毒检测套组市值为 2.9598 亿美元，预计到 2026 年将成长至 3.1686 亿美元，预计到 2032 年将达到 4.7622 亿美元，复合年增长率为 7.03%。

关键市场统计数据
基准年 2025 2.9598亿美元
预计年份：2026年 3.1686亿美元
预测年份 2032 4.7622亿美元
复合年增长率 (%) 7.03%

人类副流感病毒诊断的全面概述：为决策者阐明目的、主要读者、范围和实际背景

鑑于人类副流感病毒的普遍性和临床意义，需要一份清晰易懂的概述，以明确临床和公共卫生相关人员的诊断重点。本导言阐明了报告的目的，明确了主要读者——临床医生、检查室主任、诊断开发人员和政策顾问——并概述了报告涵盖的技术模式、产品形式、终端用户环境、检体类型和应用领域。此外，本导言也表明，报告着重于营运和策略方面的见解，而非抽象的统计预测。

技术创新、监管调整和供应链韧性如何推动副流感诊断策略和部署的变革性变化

技术进步、临床需求变化以及公共卫生重点的演变正在重塑副流感病毒的诊断模式。检测化学、仪器小型化和检体自动化处理的最新趋势正在加速向更快速、更一体化的诊断工作流程转变。同时，呼吸道症候群多重检测的日益普及也影响着检测设计和采购的考量，人们期望副流感病毒检测能够与流感病毒、呼吸道合胞病毒（RSV）和新兴病原体检测组合相容。

评估美国近期关税调整对诊断试剂盒生产、采购和检查室供应策略的营运和采购影响

美国近期采取的关税措施为诊断试剂盒和试剂的製造商、经销商和最终用户带来了多重考虑。关税调整将影响进口零件（例如一次性塑胶製品、特殊酵素和仪器零件）的到岸成本，进而可能影响采购时机、库存策略和生产本地化等方面的决策。因此，各机构正在重新审视供应商合约和筹资策略，以应对成本波动，同时确保关键投入品的持续供应。

将技术、产品分类、终端用户环境、检体基质和应用领域与诊断决策联繫起来的详细細項分析

深入了解技术和产品细分对于使诊断开发和采购策略与临床及营运需求保持一致至关重要。基于技术的分类可分为免疫检测和分子诊断。免疫检测包括化学冷光免疫检测、酵素免疫分析法和侧向流动免疫检测，每种方法在通量、灵敏度和照护现场适用性方面各有优劣。分子方法包括等温扩增、次世代定序和即时PCR，每种方法在分析解析度、多重检测能力和检查室复杂度方面各有不同。

区域法规结构、医疗基础设施多样性和生产能力将如何影响全球市场副流感诊断的策略决策

区域趋势将在决定全球医疗系统中诊断技术的可用性、监管路径和应用模式方面发挥关键作用。在美洲，成熟的实验室网路和完善的采购流程正在促进高通量分子平台和检验的照护现场方案的整合，重点在于互通性和数据连接性，以支援临床决策。在欧洲、中东和非洲地区，不同的法规结构和医疗基础设施导致了不同的应用模式。一些市场优先考虑集中式检查室检测和严格的合格评定，而另一些市场则越来越依赖分散式解决方案，以扩大资源匮乏地区的医疗服务覆盖范围。

产业竞争与合作趋势凸显了平台柔软性、伙伴关係策略与服务导向模式对副流感诊断的影响。

诊断公司之间的竞争持续加速产品创新、伙伴关係活动和策略整合。主要企业正投资于平台柔软性，以同时满足照护现场和集中式检查室的需求，优先考虑模组化仪器设计和可适用于各种呼吸道检测专案的检测化学方法。检测开发人员和仪器製造商之间的策略联盟正在加速需要整合检体处理和数位化读数的检测方法的临床应用。同时，以服务为导向的经营模式强调远端监控、培训和耗材补充，以保障收入来源和客户运作。

产业领导者可以采取哪些切实可行的策略重点和营运措施来增强诊断能力、提高供应链韧性并加强监管准备？

为了掌握诊断领域的机会并降低营运风险，产业领导者应采取切实可行的优先事项。首先，优先验证所有预期检体类型和终端使用者环境下的检测检验，以确保效能稳定可靠，并能轻鬆整合到临床工作流程中。其次，拓展供应商关係，并考虑采用模组化生产策略，以降低单点故障风险，同时确保品质和合规性。第三，增加对平台互通性和连接性的投资，以满足医疗系统对无缝资料交换的需求，并支援多病原体检测策略。

一种透明且可复製的调查方法，结合了对关键相关人员的访谈、技术文献综述和基于情境的供应链分析。

本报告的调查方法结合了多方面的证据综合、专家咨询和系统性检验，旨在得出切实可行的见解。主要研究包括对临床实验室主任、诊断研发负责人、采购专业人员和公共卫生从业人员的访谈，以确保研究结果与实际情况紧密结合。次要研究则利用了同行评审文献、监管指南、技术白皮书和产品文檔，以支持对技术性能特征、工作流程影响和监管路径的分析。

一份简明扼要的摘要，重点阐述了整合技术效能、工作流程相容性和供应链弹性的持续诊断的影响。

总之，副流感病毒诊断正朝着分析严谨性和操作实用性之间的平衡发展。免疫检测和分子诊断技术的进步、照护现场（POC​​）能力的提升以及供应链意识的增强，共同推动着检测方法的设计、检验和部署方式的变革。因此，相关人员必须将技术效能与工作流程相容性、法规遵循和采购韧性等因素结合，才能达到持续的临床应用效果。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 人类副流感病毒检测套组市场（依产品分类）

  • 等温套件
  • 快速检测套组
  • 即时PCR试剂盒

9. 按技术分類的人类副流感病毒检测套组市场

  • 免疫检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 侧向流动免疫检测
  • 分子
    • 等温扩增
    • 次世代定序
    • 即时PCR

第十章 人类副流感病毒检测套组市场（依最终用户划分）

  • 学术研究机构
  • 诊断检查室
  • 医院
  • 照护现场中心

第十一章：按检体类型分類的人类副流感病毒检测套组市场

  • 鼻咽拭子
  • 口咽拭子
  • 痰

第十二章 人类副流感病毒检测套组市场（依应用划分）

  • 临床诊断
  • 流行病学调查
  • 调查

第十三章 各地区人类副流感病毒检测套组市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 人类副流感病毒检测套组市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国人副流感病毒检测套组市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国人类副流感病毒检测套组市场

第十七章：中国人副流感病毒检测套组市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Anatolia Tani ve Biyoteknoloji Urunleri Sanayi ve Ticaret AS
  • Becton, Dickinson and Company
  • Beijing OriginGene-Tech Biotechnology Co.,Ltd
  • BioFire Diagnostics
  • bioMerieux SA
  • Certest Biotec
  • Cortez Diagnostics
  • Daan Gene Co., Ltd.
  • DBLue Medical
  • Genematrix Inc.
  • GenMark Diagnostics, Inc.
  • Hologic Inc.
  • Huwel Lifesciences
  • Luminex Corporation
  • QIAGEN NV
  • QuidelOrtho
  • R-Biopharm AG
  • Roche Holding AG
  • Seegene
  • Thermo Fisher Scientific
  • Xian Tianlong Science and Technology
  • Zhejiang Orient Gene
Product Code: MRR-7B550E008DD9

The Human Parainfluenza Virus Test Kits Market was valued at USD 295.98 million in 2025 and is projected to grow to USD 316.86 million in 2026, with a CAGR of 7.03%, reaching USD 476.22 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 295.98 million
Estimated Year [2026] USD 316.86 million
Forecast Year [2032] USD 476.22 million
CAGR (%) 7.03%

Comprehensive orientation to human parainfluenza virus diagnostics that clarifies purpose, audience, scope, and practical context for decision-makers

The prevalence and clinical significance of human parainfluenza viruses require a clear, accessible briefing that frames diagnostic priorities for clinical and public health stakeholders. This introduction establishes the purpose of the report, clarifies the intended audience of clinicians, laboratory directors, diagnostic developers, and policy advisors, and outlines the scope of coverage across technological modalities, product formats, end-user environments, sample types, and applications. It also signals the report's emphasis on operational and strategic insights rather than abstract statistical projections.

By situating parainfluenza testing within contemporary diagnostic pathways and recent shifts in respiratory pathogen detection, the introduction provides a concise orientation to the diagnostic challenges and opportunities. It highlights the interplay between rapid point-of-care decision-making and laboratory-based confirmatory workflows, and it underscores how diagnostic performance, workflow integration, regulatory constraints, and supply chain robustness shape deployment choices. Taken together, this opening section ensures readers are equipped to interpret subsequent analysis and apply findings to procurement, development, and clinical pathway design.

How technological innovation, regulatory adaptation, and supply chain resilience are driving transformative shifts in parainfluenza diagnostic strategies and deployment

Technological advances, shifting clinical expectations, and evolving public health priorities are reshaping the diagnostic landscape for parainfluenza viruses. Recent developments in assay chemistry, instrumentation miniaturization, and automated sample processing have accelerated the move toward faster, more integrated diagnostic workflows. In tandem, the prioritization of multiplex testing for respiratory syndromes has increased expectations that parainfluenza assays will interoperate with panels for influenza, RSV, and emergent pathogens, thereby influencing test design and purchasing considerations.

Concurrently, regulatory environments and reimbursement pathways have adapted to prioritize diagnostic responsiveness during respiratory seasons and outbreak events, creating pressure for assays that can demonstrate robust sensitivity and specificity across diverse sample types. The continued expansion of point-of-care testing capabilities, supported by simplified user interfaces and connectivity features for electronic health records, is enabling broader deployment in emergency departments, urgent care centers, and decentralized clinics. These dynamics are complemented by supply chain resilience initiatives that emphasize diversified reagent sources, modular instrument platforms, and onshore production capacity to mitigate disruption risks. Together, these shifts are prompting both incremental and transformative changes in how diagnostics are developed, validated, and adopted across care settings.

Assessing the operational and procurement consequences of recent United States tariff adjustments on diagnostic kit production, sourcing, and laboratory supply strategies

Recent tariff actions in the United States have introduced a layered set of considerations for manufacturers, distributors, and end users of diagnostic kits and reagents. Tariff adjustments affect the landed cost of imported components such as plastic disposables, specialized enzymes, and instrument parts, and they can influence decisions about procurement timing, inventory strategies, and localization of manufacturing. As a result, organizations have been reexamining supplier contracts and sourcing strategies to manage cost volatility while maintaining uninterrupted access to critical inputs.

In practical terms, higher import levies increase the imperative for suppliers to pursue cost-saving process innovations and negotiate longer-term supply agreements. Stakeholders are balancing these pressures against the need to preserve assay quality and regulatory compliance, recognizing that substitution of inputs or changes to manufacturing sites may require additional validation and regulatory communication. For healthcare providers and laboratories, tariff-driven cost shifts can lead to re-prioritization of test menus and renegotiation of purchasing terms, while procurement teams weigh the trade-offs between near-term cost containment and long-term resilience. Looking ahead, the tariff environment is likely to be an ongoing operational consideration that shapes procurement cycles, supplier diversification strategies, and conversations about domestic manufacturing investment.

In-depth segmentation analysis linking technologies, product classes, end-user environments, sample matrices, and application domains to diagnostic decision-making

A granular understanding of technological and product segmentation is essential to align diagnostic development and purchasing strategies with clinical and operational needs. Based on technology, the landscape divides into Immunoassay and Molecular approaches. Immunoassay methodologies include chemiluminescence immunoassay, enzyme linked immunosorbent assay, and lateral flow immunoassay, each offering distinct trade-offs in throughput, sensitivity, and suitability for point-of-care use. Molecular methods encompass isothermal amplification, next generation sequencing, and real time PCR, providing varying depth of analytical resolution, multiplexing capacity, and laboratory complexity.

From a product perspective, diagnostic offerings are typically categorized as isothermal kits, rapid test kits, and real time PCR kits, which align with differing operational priorities such as turnaround time, analytical sensitivity, and integration with laboratory information systems. End-user segmentation highlights that academic and research institutes, diagnostic laboratories, hospitals, and point of care centers require tailored assay characteristics, validation support, and service models; academic and research settings often demand flexible platforms for exploratory studies, while hospitals prioritize throughput and robustness, and point of care centers emphasize ease of use and immediate actionable results. Sample-type considerations-nasopharyngeal swab, oropharyngeal swab, and sputum-affect pre-analytical handling, biosafety protocols, and assay sensitivity profiles, requiring developers to validate performance across relevant matrices. Finally, application-driven segmentation separates clinical diagnosis, epidemiological surveillance, and research use, each imposing distinct requirements for regulatory documentation, data reporting, and long-term specimen archiving. Understanding these segment boundaries enables stakeholders to match diagnostic attributes to clinical workflows and policy objectives in a way that optimizes clinical utility and operational efficiency.

How regional regulatory frameworks, healthcare infrastructure diversity, and manufacturing capacity shape strategic decisions for parainfluenza diagnostics across global markets

Regional dynamics play a decisive role in shaping diagnostics availability, regulatory pathways, and adoption patterns across global healthcare systems. The Americas exhibit mature laboratory networks and established procurement channels that favor integration of high-throughput molecular platforms and validated point-of-care solutions, with emphasis on interoperability and data connectivity for clinical decision support. Europe, the Middle East & Africa feature a heterogeneous set of regulatory frameworks and healthcare infrastructures that drive diverse adoption patterns: some markets prioritize centralized laboratory testing and stringent conformity assessments, while others increasingly rely on decentralized solutions to expand access in under-resourced areas.

In the Asia-Pacific region, strong domestic manufacturing capabilities, rapid adoption of automation, and robust public health testing programs support a dynamic environment for both innovative assay development and scaled distribution. Across regions, differences in reimbursement, laboratory accreditation standards, and supply chain architecture influence how diagnostic manufacturers prioritize regulatory filings, distribution partnerships, and local service models. Moreover, regional public health priorities and seasonal respiratory patterns shape demand planning and the types of assays that gain traction in clinical practice, requiring stakeholders to tailor commercial and operational strategies to regional nuances while maintaining core performance and compliance standards.

Competitive and collaborative industry trends highlighting platform flexibility, partnership strategies, and service-oriented models influencing parainfluenza diagnostics

Competitive dynamics among diagnostic companies continue to accelerate product innovation, partnership activity, and strategic consolidation. Leading firms are investing in platform flexibility that supports both point-of-care and centralized laboratory deployments, prioritizing modular instrument designs and assay chemistries that can be adapted across respiratory panels. Strategic collaborations between assay developers and instrument manufacturers are facilitating faster time-to-clinical-use for assays that require integrated sample processing and digital readouts, while service-oriented business models emphasize remote monitoring, training, and consumable replenishment to protect revenue streams and customer uptime.

In parallel, nimble developers are differentiating through focused specialization on rapid test formats or cutting-edge molecular methods such as isothermal amplification and sequencing-based approaches that provide enhanced resolution for surveillance and research applications. Procurement and clinical laboratory leaders are responding by demanding robust post-market support, transparent performance data across relevant sample types, and clear pathways for regulatory compliance. This environment is driving a blend of competition and cooperation where cross-licensing, distribution partnerships, and localized manufacturing agreements are common strategies to accelerate market access and sustain supply continuity.

Practical strategic priorities and operational actions that industry leaders can implement to strengthen diagnostics performance, supply resilience, and regulatory readiness

To capitalize on diagnostic opportunities while mitigating operational risks, industry leaders should adopt a set of pragmatic, actionable priorities. First, prioritize assay validation across the full range of anticipated sample types and end-user environments to ensure consistent performance and ease of integration into clinical workflows. Second, diversify supplier relationships and consider modular manufacturing strategies that reduce exposure to single-point disruptions while preserving quality and regulatory compliance. Third, invest in platform interoperability and connectivity to meet healthcare system demands for seamless data exchange and to support multi-pathogen testing strategies.

Additionally, companies should pursue regulatory engagement early in the product lifecycle to clarify documentation expectations and to expedite market access. Commercial teams should align product portfolios with regional needs, offering differentiated service models for high-volume laboratories versus decentralized point-of-care settings. Finally, cultivate partnerships with public health authorities and research institutions to validate assay utility in surveillance and outbreak contexts, thereby reinforcing the public health value proposition and strengthening institutional relationships that support long-term adoption.

Transparent and reproducible research methodology combining primary stakeholder interviews, technical literature synthesis, and scenario-based supply chain analysis

The research methodology underpinning this report combines multi-source evidence synthesis, expert consultation, and structured validation to produce actionable insights. Primary research included interviews with clinical laboratory directors, diagnostic development leaders, procurement specialists, and public health practitioners to ground findings in operational realities. Secondary research drew on peer-reviewed literature, regulatory guidance, technical whitepapers, and product documentation to corroborate technology performance characteristics, workflow implications, and regulatory pathways.

Analytical techniques incorporated comparative technology assessment, value chain mapping, and scenario-based supply chain stress testing to explore how different variables interact under realistic operational constraints. Quality assurance processes included cross-validation of interview data against independent technical sources and a review cycle with subject matter experts to ensure factual accuracy and relevance. Throughout, emphasis was placed on transparency of assumptions, reproducibility of methods, and clear linkage between evidence and recommendations so that readers can adapt insights to their specific strategic and operational contexts.

Concise concluding synthesis emphasizing integration of technical performance, workflow suitability, and supply resilience for enduring diagnostic impact

In summary, parainfluenza diagnostics are converging toward solutions that balance analytical rigor with operational practicality. Advances in immunoassay and molecular methods, coupled with expanding point-of-care capabilities and heightened supply chain awareness, are reshaping how assays are designed, validated, and deployed. Stakeholders must therefore integrate technical performance with considerations around workflow fit, regulatory alignment, and sourcing resilience to achieve sustained clinical impact.

Strategic choices made today regarding platform flexibility, supplier diversification, and regional market alignment will determine the success of diagnostic programs in clinical and public health settings. By focusing on validated performance across relevant sample types and end-user environments, and by proactively engaging with regulatory and procurement processes, organizations can enhance readiness to respond to seasonal surges and emergent respiratory threats while preserving operational stability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Parainfluenza Virus Test Kits Market, by Product

  • 8.1. Isothermal Kits
  • 8.2. Rapid Test Kits
  • 8.3. Real Time Pcr Kits

9. Human Parainfluenza Virus Test Kits Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Chemiluminescence Immunoassay
    • 9.1.2. Enzyme Linked Immunosorbent Assay
    • 9.1.3. Lateral Flow Immunoassay
  • 9.2. Molecular
    • 9.2.1. Isothermal Amplification
    • 9.2.2. Next Generation Sequencing
    • 9.2.3. Real Time Pcr

10. Human Parainfluenza Virus Test Kits Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Point Of Care Centers

11. Human Parainfluenza Virus Test Kits Market, by Sample Type

  • 11.1. Nasopharyngeal Swab
  • 11.2. Oropharyngeal Swab
  • 11.3. Sputum

12. Human Parainfluenza Virus Test Kits Market, by Application

  • 12.1. Clinical Diagnosis
  • 12.2. Epidemiological Surveillance
  • 12.3. Research

13. Human Parainfluenza Virus Test Kits Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Human Parainfluenza Virus Test Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Human Parainfluenza Virus Test Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Human Parainfluenza Virus Test Kits Market

17. China Human Parainfluenza Virus Test Kits Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Anatolia Tani ve Biyoteknoloji Urunleri Sanayi ve Ticaret A.S.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Beijing OriginGene-Tech Biotechnology Co.,Ltd
  • 18.9. BioFire Diagnostics
  • 18.10. bioMerieux SA
  • 18.11. Certest Biotec
  • 18.12. Cortez Diagnostics
  • 18.13. Daan Gene Co., Ltd.
  • 18.14. DBLue Medical
  • 18.15. Genematrix Inc.
  • 18.16. GenMark Diagnostics, Inc.
  • 18.17. Hologic Inc.
  • 18.18. Huwel Lifesciences
  • 18.19. Luminex Corporation
  • 18.20. QIAGEN N.V.
  • 18.21. QuidelOrtho
  • 18.22. R-Biopharm AG
  • 18.23. Roche Holding AG
  • 18.24. Seegene
  • 18.25. Thermo Fisher Scientific
  • 18.26. Xian Tianlong Science and Technology
  • 18.27. Zhejiang Orient Gene

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY POINT OF CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY POINT OF CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY POINT OF CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 151. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 172. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 175. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 183. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA HUMAN PARAINFLUENZA VIRUS TEST KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)